论文部分内容阅读
目的为阐明小细胞肺癌 (SCL C)患者血清神经元特异性烯醇化酶 (NSE)在该病的诊断、化疗和复发中的意义以及 NSE半衰期与 SCL C复发的关系。方法用单克隆抗体 EL ISA一步法测定了 NSE含量。结果 NSE诊断 SCL C的敏感性、特异性及准确度分别为 81.8%、91.6 %和 89.5 % ;其中局限性 (L D) SCL C和扩展性 (ED) SCL C患者的阳性率分别为 72 .7%和90 .9% ;NSE的半衰期大于 2 0 d者 ,其复发在发病 43～ 193d前即被发现 ,NSE半衰期预测 SCL C复发敏感性为 83.3%。结论血清 NSE检测对 SCL C与 NSCL C的鉴别诊断具有重要意义 ,NSE半衰期预测 SCL C复发的敏感性优于 NSE含量测定。
Objective To elucidate the significance of serum neuron-specific enolase (NSE) in the diagnosis, chemotherapy, and recurrence of the disease in patients with small cell lung cancer (SCL C) and the relationship between NSE half-life and recurrence of SCL C. Methods One-step determination of NSE with monoclonal antibody EL ISA was performed. Results The sensitivity, specificity and accuracy of NCL in the diagnosis of SCL C were 81.8%, 91.6% and 89.5%, respectively; the positive rates of LD SCL C and ED SCL C were 72.7, respectively. % and 90.9%; NSE half-life is greater than 20 days, the recurrence was found before the onset of 43 ~ 193d, NSE half-life predicted SCL C recurrence sensitivity was 83.3%. Conclusion The serum NSE test has important significance in the differential diagnosis of SCL C and NSCL C. The half-life of NSE predicts that the recurrence of SCL C is more sensitive than that of NSE.